The Alzheimer's Association International Conference 2016 (AAIC) is the world's largest forum for the Alzheimer’s disease research community. This webinar features Dr. Zara Fulton of Biomedtracker and Dr. Maha Elsayed of Datamonitor Healthcare, both of whom attended the conference, as they provide a wrap-up of the latest Alzheimer’s disease clinical study results including:

• The latest results from the LMTX (TauRx Therapeutics) Phase III trial, the first and only tau aggregation inhibitor to reach Phase III clinical development
• The Phase IIa efficacy data for Anavex 2-73 (AVXL), and other less explored mechanisms of action in clinical development
• The failure of the 5-HT6 receptor antagonist PF-05212377 (PFE) Phase II study and the implications for other clinical trials of drugs of this class

The webinar can be viewed here.